Authors of the MEASURE 3 study have shared their end‐of‐study 3‐year efficacy and safety results of secukinumab, 150 mg and 300 mg, among patients with active ankylosing spondylitis. Find out what the...
Jessica Ailani, MD, answers our questions about new developments in therapeutics and technology, as well as overcoming the challenges of diagnosing and treating migraine.
Because less-invasive, nonsurgical approaches are needed to treat severe emphysema, authors of a new study compared the safety and efficacy of the Spiration Valve System with optimal medical management. ...
In addition to lowering the number of monthly migraine days, galcanezumab may also reduce the need for acute medication in patients with migraine. A new post-hoc analysis presented at the American Headache...
In a phase 2b/3 study, a new orally administered CGRP receptor antagonist showed positive results in preventing migraines. Results were presented at the American Headache Society’s 61st Annual Scientific...
Study results presented at the American Headache Society’s 61st Annual Scientific Sessions highlight a non-invasive alternative to opioids for the treatment of chronic migraine.
Dopamine is known to regulate striatal function and learning. In a new study, researchers applied this knowledge to determine whether post-stroke administration of dopaminergic therapy—in addition to...
In a new study, researchers aimed to better understand the effects of alcohol septal ablation for patients presenting with Fabry disease and left ventricular hypertrophy.
Researchers evaluated data from more than 200,000 new users of histamine H2 receptor antagonists or proton pump inhibitors to estimate all-cause mortality and cause-specific mortality associated with the...
Authors of a new study aimed to determine whether racial disparities in receiving pulmonary rehabilitation are explained by density of pulmonary rehabilitation programs and other community-level factors. ...
